MP68-16 REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR NOVEL HORMONAL THERAPY AND TAXANE USE

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP68)1 May 2024MP68-16 REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR NOVEL HORMONAL THERAPY AND TAXANE USE Umang Swami, Pedro Barata, Allison Thompson, Jonathan Assayag, Melissa Kirker, Saif Shaman, Chai Kim, Geeta Devgan, and Neeraj Agarwal Umang SwamiUmang Swami , Pedro BarataPedro Barata , Allison ThompsonAllison Thompson , Jonathan AssayagJonathan Assayag , Melissa KirkerMelissa Kirker , Saif ShamanSaif Shaman , Chai KimChai Kim , Geeta DevganGeeta Devgan , and Neeraj AgarwalNeeraj Agarwal View All Author Informationhttps://doi.org/10.1097/01.JU.0001008744.60568.e8.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Novel hormonal therapy (NHT) provides additional treatment (tx) options for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), however, the tx paradigm has shifted and systemic therapies are now tx options in earlier settings, including metastatic castration-sensitive prostate cancer. Pts who receive systemic tx in prior settings may have fewer tx options as they progress to mCRPC; questions remain about what is the best tx sequence for these pts. This study aims to document tx patterns and outcomes of pts with mCRPC who received tx in a prior setting. METHODS: A non-interventional, retrospective cohort study of pts with mCRPC in the United States was conducted using data from Flatiron Health's electronic health record database. Pts were included if they were diagnosed with mCRPC between January 1, 2016 and July 31, 2023 and received 1L tx for mCRPC as defined by Flatiron. Results were described for the total cohort and by the txs received prior to mCRPC: 1) NHT exposed only, 2) taxane exposed only, 3) NHT and taxane exposed, 4) NHT and taxane naïve. RESULTS: 4,615 pts received 1L mCRPC tx and all had received tx prior to mCRPC diagnosis; median age: 74 years; White race: 60.6%, Black race 11.2%; Gleason score ≥7: 77.4%, unknown: 16.2%. Overall, most patients were NHT and taxane naïve (n=3,425, 74.2%), 708 (15.3%) were NHT exposed only, 411 (8.9%) were taxane exposed only, and 71 (1.5%) were NHT and taxane exposed. Prior tx use differed by year and unadjusted median overall survival (mOS) from mCRPC 1L tx differed by prior tx(s) received; results are reported in the Table 1. CONCLUSIONS: The use of systemic txs in settings prior to mCRPC is increasing over time, however, majority of pts remain NHT and/or taxane naïve at mCRPC diagnosis. Unadjusted mOS from mCRPC 1L tx differed by prior tx received suggesting tx sequence may impact outcomes. Source of Funding: The study was sponsored by Pfizer © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1115 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Umang Swami More articles by this author Pedro Barata More articles by this author Allison Thompson More articles by this author Jonathan Assayag More articles by this author Melissa Kirker More articles by this author Saif Shaman More articles by this author Chai Kim More articles by this author Geeta Devgan More articles by this author Neeraj Agarwal More articles by this author Expand All Advertisement PDF downloadLoading ...